Evaluation of hepatocellular carcinoma models for preclinical studies
Drug Discovery Today: Disease Models, ISSN: 1740-6757, Vol: 2, Issue: 1, Page: 41-49
2005
- 9Citations
- 27Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Research on hepatocellular carcinoma (HCC) therapy requires appropriate models. Unfortunately, the choice of model often reflects experimental convenience rather than direct relevance to the molecular phenotype and development of the disease. This constitutes a significant obstacle for evaluating the responses to experimental treatments. Therefore, studies that compare the molecular characteristics of human and animal HCC are of enormous importance. Here, we review current models of HCC, highlighting the best candidates for future preclinical investigations.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1740675705000113; http://dx.doi.org/10.1016/j.ddmod.2005.05.009; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=21644453593&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1740675705000113; https://dx.doi.org/10.1016/j.ddmod.2005.05.009
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know